Related Experiment Video
Updated: Aug 7, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Risk factors for coronary heart disease in patients with schizophrenia
1Depeartment of Internal Diseases N1, Tbilisi State Medical University.
Insights
Patients with schizophrenia exhibit elevated cholesterol and LDL, with decreased HDL, indicating increased cardiovascular disease risk. These findings highlight the need for proactive cardiovascular risk management in this population.
Area of Science:
- Cardiology
- Psychiatry
- Metabolic Disorders
Background:
- Cardiovascular disease (CVD) is a leading global cause of mortality.
- Unhealthy cholesterol and lipid levels significantly contribute to CVD.
- Emerging evidence links mental disorders, particularly schizophrenia, to increased cardiac disease risk.
Purpose of the Study:
- To investigate cholesterol and lipid profiles in patients with schizophrenia.
- To identify potential cardiovascular disease risk factors associated with schizophrenia.
Main Methods:
- Lipid profiles, including cholesterol, HDL, LDL, and triglycerides, were measured in 40 patients with schizophrenia.
- Statistical analysis was performed to compare lipid levels with established risk thresholds.
Main Results:
- Patients with schizophrenia showed significantly higher cholesterol and LDL levels.
- HDL levels were significantly decreased in patients with schizophrenia.
- Elevated triglycerides, smoking, sedentary lifestyle, and psychosocial factors were identified as additional CVD risks.
Conclusions:
- Schizophrenia patients present with multiple cardiovascular disease risk factors, including dyslipidemia.
- These patients represent a high-risk group requiring targeted cardiovascular health interventions.
- Further research is warranted to explore the mechanisms linking schizophrenia and CVD.
Abstract:
Cardiovascular disease is the leading cause of death worldwide. As many as half of these death may be attributed to the unhealthy cholesterol and lipid levels. Elevated cholesterol levels could contribute to the increase in cardiovascular morbidity and mortality. Association between the coronary artery disease and mental disorder is less studied and documented, but several studies have demonstrated, that mental disorders increases the risk of developing cardiac disease, in particular coronary artery disease. Cholesterol and other lipids level were measured in 40 patients (n=40). Cholesterol and LDL levels in patients with schizophrenia were significantly higher and HDL was significantly decreased. Cholesterol level 180-200 mg/dl were determined in 35%, 200-235 mg/dl in 17,5%, >235 mg/dl 12,5%. HDL->35 mg/dl revealed in 37,5%. LDL 130-159 mg/dl were determined in 10%, >160 mg/dl - 20%. Triglycerides (Tg) from 150 mg/dl to 199 mg/dl were determined in 25%, from 200 mg/dl to 499 mg/dl in 12,5%. According to our study, patients with schizophrenia has some risk factors for cardiovascular heart disease such as, elevated levels of Tg and LDL-c, smoking, lack of exercise, psychosocial factors (depression, social isolation and lack of social support, low socioeconomic status) and so on. We can conclude that all these patients with schizophrenia may belong to the risk group of cardiovascular disease.
Related Concept Videos
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Coronary Artery Disease II: Pathophysiology